Some tumors maintain environments that suppress anti-cancer T cells and protect them against checkpoint inhibitor immunotherapies. To help devise ways to overcome this resistance, Dr. Curran is investigating the role that low oxygen conditions―known as hypoxia―play in preventing effective immune responses in these hard-to-treat cancers, including prostate cancer. He’s characterizing how hypoxia affects the activity of both anti-cancer T cells and pro-cancer immune cells, as well as how disrupting this hypoxia affects the immune system’s ability to eliminate cancer, both alone and in combination with checkpoint inhibitors. These insights should provide a promising path forward for identifying and developing immunotherapy approaches for prostate tumors and other tough-to-treat cancers.
The University of Texas MD Anderson Cancer Center | All Cancers, Pancreatic Cancer, Prostate Cancer | 2016
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Cell therapy development lagged in 2020, but is gaining ground again, a new CRI report shows.
CRI scientists will highlight cancer immunotherapy advances in the clinic at the 2021 ASCO annual meeting.